Literature DB >> 26542407

[Orthopaedic implant-associated infections: Update of antimicrobial therapy].

W Zimmerli1.   

Abstract

In infections related to prosthetic joints and internal fixation devices, microorganisms adhere as biofim on the surface of the implant. Biofilms are not only resistant to phagocytosis, but also to most antimicrobial agents. Therefore, spontaneous cure does never occur, and antibiotics have to be given for several months. According to traditional concepts, removal of all foreign material was considered as prerequisite for cure. Yet, during the last decades, it has been shown that staphylococcal biofilms can be eliminated by rifampin combination therapy, and Gram-negative biofilms by fluoroquinolones. However, reliable biofilm elimination is only possible, if the duration of infection does not exceed 3-4 weeks. Correct total duration of the antimicrobial therapy has never been tested in a controlled trial. Currently, treatment duration is 3 (hip prosthesis) and 6 (knee prosthesis) months in patients undergoing débridement with implant retention, one-stage exchange, and two-stage exchange with a short interval of 2-3 weeks. According to a recent observational trial, a treatment duration of 2 and 3 months, respectively, is equivalent to the longer duration in patients undergoing débridement and implant retention. The optimal surgical therapy should be chosen according to a rational algorithm. It is crucial choosing the optimal surgical intervention from the beginning, because the final functional success depends on the cure by the first attempt.

Entities:  

Keywords:  Antimicrobial agents; Bacterial adhesion; Biofilms; Microbial susceptibility testing; Staphylococcal infections

Mesh:

Substances:

Year:  2015        PMID: 26542407     DOI: 10.1007/s00132-015-3184-y

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  23 in total

1.  Short-course antibiotics for prosthetic joint infections treated with prosthesis retention.

Authors:  A-P Puhto; T Puhto; H Syrjala
Journal:  Clin Microbiol Infect       Date:  2011-11-09       Impact factor: 8.067

2.  Prosthesis failure within 2 years of implantation is highly predictive of infection.

Authors:  María Eugenia Portillo; Margarita Salvadó; Albert Alier; Lluisa Sorli; Santos Martínez; Juan Pablo Horcajada; Lluis Puig
Journal:  Clin Orthop Relat Res       Date:  2013-08-01       Impact factor: 4.176

3.  Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study.

Authors:  D Rodríguez-Pardo; C Pigrau; J Lora-Tamayo; A Soriano; M D del Toro; J Cobo; J Palomino; G Euba; M Riera; M Sánchez-Somolinos; N Benito; M Fernández-Sampedro; L Sorli; L Guio; J A Iribarren; J M Baraia-Etxaburu; A Ramos; A Bahamonde; X Flores-Sánchez; P S Corona; J Ariza
Journal:  Clin Microbiol Infect       Date:  2014-06-14       Impact factor: 8.067

Review 4.  Pathogenesis of implant-associated infection: the role of the host.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Semin Immunopathol       Date:  2011-05-21       Impact factor: 9.623

5.  The Chitranjan Ranawat Award: fate of two-stage reimplantation after failed irrigation and débridement for periprosthetic knee infection.

Authors:  J Christopher Sherrell; Thomas K Fehring; Susan Odum; Erik Hansen; Benjamin Zmistowski; Anne Dennos; Niraj Kalore
Journal:  Clin Orthop Relat Res       Date:  2011-01       Impact factor: 4.176

6.  Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections.

Authors:  S Nguyen; O Robineau; M Titecat; N Blondiaux; M Valette; C Loiez; E Beltrand; H Migaud; E Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

7.  Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections.

Authors:  A F Widmer; R Frei; Z Rajacic; W Zimmerli
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

8.  Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus.

Authors:  W Zimmerli; R Frei; A F Widmer; Z Rajacic
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

9.  Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin.

Authors:  Anne-Kathrin John; Daniela Baldoni; Manuel Haschke; Katharina Rentsch; Patrick Schaerli; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin.

Authors:  Steve P Bernier; David Lebeaux; Alicia S DeFrancesco; Amandine Valomon; Guillaume Soubigou; Jean-Yves Coppée; Jean-Marc Ghigo; Christophe Beloin
Journal:  PLoS Genet       Date:  2013-01-03       Impact factor: 5.917

View more
  4 in total

Review 1.  [Management of periprosthetic infections of the knee].

Authors:  N Renz; C Perka; A Trampuz
Journal:  Orthopade       Date:  2016-01       Impact factor: 1.087

2.  Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  Manuel Kussmann; Markus Obermueller; Florian Berndl; Veronika Reischer; Luzia Veletzky; Heinz Burgmann; Wolfgang Poeppl
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

3.  Conversion From Knee Arthrodesis Back to Arthroplasty: A Particular Challenge in Combination With Fungal Periprosthetic Joint Infection.

Authors:  Sven Frieler; Emre Yilmaz; Ryan Goodmanson; Yannik Hanusrichter; Thomas A Schildhauer; Hinnerk Baecker
Journal:  Arthroplast Today       Date:  2020-12-05

4.  Enzyme-Responsive Nanoparticles and Coatings Made from Alginate/Peptide Ciprofloxacin Conjugates as Drug Release System.

Authors:  Yannick Bourgat; Carina Mikolai; Meike Stiesch; Philipp Klahn; Henning Menzel
Journal:  Antibiotics (Basel)       Date:  2021-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.